Research programme: diabetes therapeutics - Hyundai Pharmaceuticals

Drug Profile

Research programme: diabetes therapeutics - Hyundai Pharmaceuticals

Alternative Names: GPR-6277; HD-0472936; HD-2355; HD-2356; HD-2936; HD-6277; HOB-046; HOB-047

Latest Information Update: 29 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hyundai Pharmaceutical
  • Class
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors; FFAR1 protein stimulants; GPR119 protein agonists; Peroxisome proliferator-activated receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 09 Jun 2017 Pharmacodynamics data from a preclinical trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 09 Jun 2017 Pharmacokinetics data from a preclinical trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 09 Jun 2017 Safety data from a preclinical trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top